Humacyte Enters Sales Agreement with TD Securities

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialAn announcement from Humacyte ( (HUMA) ) is now available. On December 16, 2025, Humacyte, Inc. entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell its common stock, with an aggregate offering price of up to $60 million. The proceeds from this offering are intended to support the commercialization of Symvess® for vascular trauma, further development of Humacyte’s product pipeline, and general corporate purposes. The agreement allows TD Cowen to sell shares through various methods, including at-the-market offerings, and includes provisions for termination under specific conditions. The company has agreed to pay a commission to TD Cowen and has made customary representations and warranties as part of the agreement. The most recent analyst rating on (HUMA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page. Spark’s Take on HUMA Stock According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral. Humacyte’s overall stock score reflects significant financial and technical challenges. The lack of revenue, persistent losses, and negative equity weigh heavily on the financial performance. Technical analysis indicates bearish momentum. The valuation metrics suggest the stock may be overpriced given the negative P/E ratio and absence of dividends. The earnings call offered some optimism regarding future growth due to FDA approvals and product launches, but these are long-term prospects amid current financial difficulties. Recent corporate events provide mixed signals with potential legal risks and a successful capital raise. To see Spark’s full report on HUMA stock, click here. More about Humacyte Humacyte, Inc. operates in the biotechnology industry, focusing on the development and commercialization of bioengineered human tissue. The company is particularly involved in creating products for vascular trauma and has a pipeline of product candidates aimed at addressing various medical needs. Average Trading Volume: 5,428,726 Technical Sentiment Signal: Sell Current Market Cap: $245.3M For a thorough assessment of HUMA stock, go to TipRanks’ Stock Analysis page.